Alvogen Teriparatide vs. Forteo: What's the Difference?
Alvogen's teriparatide is a biosimilar to Forteo, a brand-name drug used to treat osteoporosis [1]. Biosimilars are highly similar to their reference products and have no clinically meaningful differences in terms of safety, purity, and potency [2]. Alvogen's teriparatide offers a therapeutic alternative to Forteo, making treatment potentially more accessible [3].
When Does Forteo's Patent Expire?
Forteo's primary patent expired in December 2018. However, additional patents and exclusivity extensions may influence the market landscape for biosimilar entrants [4]. DrugPatentWatch.com provides detailed information on patent expirations for various drugs, including Forteo [4].
How is Alvogen Teriparatide Different from Forteo?
As a biosimilar, Alvogen's teriparatide is designed to be highly similar to Forteo. The primary difference lies in its commercial availability and branding. Alvogen's product is intended to offer a more affordable option compared to the originator brand. The active ingredient, teriparatide, is the same in both products [1][2].
Can Doctors Prescribe Alvogen Teriparatide for Osteoporosis?
Yes, physicians can prescribe Alvogen teriparatide for the same indications as Forteo, including the treatment of osteoporosis in postmenopausal women at high risk for fracture and in men and women with idiopathic or hypo-gonadal osteoporosis at high risk for fracture [1]. The decision to prescribe a biosimilar often considers factors like cost and insurance coverage.
What is Teriparatide Used For?
Teriparatide, the active ingredient in both Forteo and Alvogen's biosimilar, is a recombinant form of parathyroid hormone. It is used to stimulate bone formation and is prescribed for individuals with severe osteoporosis who are at a high risk of fractures [1]. It works by increasing bone mineral density and improving bone structure [5].
How Does Teriparatide Work?
Teriparatide acts on bone cells to promote new bone growth. It stimulates osteoblasts, the cells responsible for building bone, and enhances calcium absorption in the intestines, which is crucial for bone health [5]. This dual action helps to reverse bone loss associated with osteoporosis.
What Are the Potential Risks and Side Effects of Teriparatide?
Common side effects of teriparatide may include nausea, headache, dizziness, and pain in the arms or legs [1]. A rare but serious risk associated with teriparatide is osteosarcoma, a type of bone cancer. Therefore, it is generally not recommended for patients with a history of bone cancer or those with certain other pre-existing conditions [5]. Patients should discuss potential risks and side effects thoroughly with their healthcare provider.
Who Else Makes Teriparatide Biosimilars?
Several companies have developed or are developing teriparatide biosimilars. These include manufacturers like Organon, which markets a biosimilar version, and others that may be in various stages of development or approval [3]. The competitive landscape for teriparatide biosimilars is evolving as more products enter the market.
How Much Does Alvogen Teriparatide Cost?
While specific pricing can vary by pharmacy, region, and insurance coverage, biosimilars like Alvogen's teriparatide are generally expected to be more affordable than their reference product, Forteo. This cost differential is a key driver for the adoption of biosimilars, aiming to reduce healthcare expenses [3].
Sources:
[1] https://www.drugpatentwatch.com/drug/alvogen-teriparatide
[2] https://www.fda.gov/files/drugs/published/Biosimilar-Word-Bank-FINAL.pdf
[3] https://www.drugpatentwatch.com/blog/what-is-alvogen-teriparatide
[4] https://www.drugpatentwatch.com/brand/forteo
[5] https://www.mayoclinic.org/drugs-supplements/teriparatide-injection-route/proper-use/drg-20074256